clinical trial · NCT06979076
A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL
MingSight Pharmaceuticals, Inc·phase2·not yet recruiting·n = 12
CLL (Chronic Lymphocytic Leukemia)SLL (Small Lymphocytic Lymphoma)MS-553, DS1MS-553, DS2
brief summary
A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
started
Jul 1, 2026
primary completion
Sep 1, 2028
completion
Dec 1, 2028
last updated
Sep 29, 2025
official title
A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol